Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Boston Scientific (BSX) Any Comments??? -- Ignore unavailable to you. Want to Upgrade?

To: yard_man who wrote (396)	7/9/1998 8:15:00 PM
From: John Carragher	Read Replies (1) \| Respond to of 798

Boston Scientific is projected to report second-quarter net income of 40 cents a share, down from 45 cents a year earlier, according to First Call. As has been true for the last few quarters, the Natick, Mass., company's results were hurt by its lack of an FDA-approved coronary stent. Still, Boston Scientific's angioplasty-balloon franchise managed to maintain market share in the U.S. even without the Nir stent, said Dain Rauscher Wessels analyst Sanjiv Arora said.